Aussie first hits lucrative market

Roche could be set to disrupt a lucrative market with the launch of Australia's first continuous drug-delivery system for neovascular (wet) age-related macular degeneration (nAMD), following TGA approval of the company's Susvimo for use with the already approved Contivue ocular implant.

To see the whole article please log in.

Christine Spiteri

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here